Hikma Pharmaceuticals (LON:HIK) Trading Down 14.1% – Time to Sell?

Hikma Pharmaceuticals PLC (LON:HIK)’s share price traded down 14.1% on Thursday . The company traded as low as GBX 1,522 and last traded at GBX 1,522. 166,325,172 shares changed hands during trading, an increase of 7,989% from the average session volume of 2,056,107 shares. The stock had previously closed at GBX 1,771.

Analyst Upgrades and Downgrades

Several research firms recently commented on HIK. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,600 price objective on shares of Hikma Pharmaceuticals in a report on Thursday, August 7th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating on the stock in a research note on Tuesday, August 12th. Berenberg Bank lowered their target price on shares of Hikma Pharmaceuticals from GBX 2,560 to GBX 2,510 and set a “buy” rating on the stock in a research note on Thursday, October 16th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Hikma Pharmaceuticals from GBX 2,600 to GBX 2,500 and set an “overweight” rating on the stock in a research note on Friday, August 8th. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of GBX 2,615.

Hikma Pharmaceuticals Stock Performance

The company’s 50-day moving average price is GBX 1,734.94 and its two-hundred day moving average price is GBX 1,896.07. The company has a debt-to-equity ratio of 55.82, a quick ratio of 1.27 and a current ratio of 1.66. The stock has a market cap of £3.37 billion, a PE ratio of 9.11, a PEG ratio of 2.38 and a beta of 0.41.

Insider Buying and Selling at Hikma Pharmaceuticals

In related news, insider Mazen Darwazah acquired 14,000 shares of the stock in a transaction dated Tuesday, September 16th. The shares were purchased at an average price of GBX 1,603 per share, for a total transaction of £224,420. Also, insider Laura Balan Balan acquired 3,500 shares of the stock in a transaction dated Friday, August 22nd. The shares were bought at an average price of GBX 1,821 per share, for a total transaction of £63,735. Company insiders own 17.77% of the company’s stock.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.